Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Raffaele Scarpa

Showing results (101-110 of 211) with videos related to

Pageof 22
Sort By:
Open Access Rheumatology : Research and Reviews|August 8, 2019
Biomarkers of subclinical atherosclerosis in patients with psoriatic arthritisRosario Peluso, Francesco Caso, Marco Tasso, et al.
Clinical and Experimental Rheumatology|May 13, 2015
Effects of tumor necrosis factor-α inhibitors in mothers and daughters concordant for HLA-B27-positive ankylosing spondylitisFrancesco Caso, Luisa Costa, Antonio Del Puente, et al.
Arthritis and Rheumatism|October 4, 2005
Distribution of HLA-B27 subtypes in Sardinia and continental Italy and their association with spondylarthropathiesFabiana Paladini, Egisto Taccari, Maria Teresa Fiorillo, et al.
Expert Opinion on Drug Safety|December 8, 2016
Influence of anti-TNF immunogenicity on safety in rheumatic disease: a narrative reviewAndrea Matucci, Daniele Cammelli, Fabrizio Cantini, et al.
Autoimmunity Reviews|May 8, 2020
Interleukin-17A (IL-17A), a key molecule of innate and adaptive immunity, and its potential involvement in COVID-19-related thrombotic and vascular mechanismsFederica Raucci, Adel Abo Mansour, Gian Marco Casillo, et al.
Clinical Rheumatology|January 13, 2010
Comparison of effectiveness and safety of infliximab, etanercept, and adalimumab in psoriatic arthritis patients who experienced an inadequate response to previous disease-modifying antirheumatic drugsMariangela Atteno, Rosario Peluso, Luisa Costa, et al.
Clinical and Experimental Rheumatology|August 30, 2024
Psoriatic dactylitis: from immunopathogenesis to anti-cytokine and targeted synthetic therapiesMauro Fatica, Paola Triggianese, Paola Conigliaro, et al.
Clinical and Experimental Rheumatology|February 25, 2011
The effectiveness of a biologic agent on axial manifestations of psoriatic arthritis. A twelve months observational study in a group of patients treated with etanerceptEnnio Lubrano, Antonio Spadaro, Antonio Marchesoni, et al.
Clinical Rheumatology|November 22, 2007
The effectiveness of a traditional therapeutical approach in early psoriatic arthritis: results of a pilot randomised 6-month trial with methotrexateRaffaele Scarpa, Rosario Peluso, Mariangela Atteno, et al.
Expert Review of Clinical Immunology|March 10, 2020
Metabolic Syndrome and psoriatic arthritis: considerations for the clinicianFrancesco Caso, Maria Sole Chimenti, Luca Navarini, et al.
Pageof 22

Showing results (101-110 of 211) with videos related to

Sort By:
Pageof 22
Open Access Rheumatology : Research and Reviews|August 8, 2019
Biomarkers of subclinical atherosclerosis in patients with psoriatic arthritisRosario Peluso, Francesco Caso, Marco Tasso, et al.
Clinical and Experimental Rheumatology|May 13, 2015
Effects of tumor necrosis factor-α inhibitors in mothers and daughters concordant for HLA-B27-positive ankylosing spondylitisFrancesco Caso, Luisa Costa, Antonio Del Puente, et al.
Arthritis and Rheumatism|October 4, 2005
Distribution of HLA-B27 subtypes in Sardinia and continental Italy and their association with spondylarthropathiesFabiana Paladini, Egisto Taccari, Maria Teresa Fiorillo, et al.
Expert Opinion on Drug Safety|December 8, 2016
Influence of anti-TNF immunogenicity on safety in rheumatic disease: a narrative reviewAndrea Matucci, Daniele Cammelli, Fabrizio Cantini, et al.
Autoimmunity Reviews|May 8, 2020
Interleukin-17A (IL-17A), a key molecule of innate and adaptive immunity, and its potential involvement in COVID-19-related thrombotic and vascular mechanismsFederica Raucci, Adel Abo Mansour, Gian Marco Casillo, et al.
Clinical Rheumatology|January 13, 2010
Comparison of effectiveness and safety of infliximab, etanercept, and adalimumab in psoriatic arthritis patients who experienced an inadequate response to previous disease-modifying antirheumatic drugsMariangela Atteno, Rosario Peluso, Luisa Costa, et al.
Clinical and Experimental Rheumatology|August 30, 2024
Psoriatic dactylitis: from immunopathogenesis to anti-cytokine and targeted synthetic therapiesMauro Fatica, Paola Triggianese, Paola Conigliaro, et al.
Clinical and Experimental Rheumatology|February 25, 2011
The effectiveness of a biologic agent on axial manifestations of psoriatic arthritis. A twelve months observational study in a group of patients treated with etanerceptEnnio Lubrano, Antonio Spadaro, Antonio Marchesoni, et al.
Clinical Rheumatology|November 22, 2007
The effectiveness of a traditional therapeutical approach in early psoriatic arthritis: results of a pilot randomised 6-month trial with methotrexateRaffaele Scarpa, Rosario Peluso, Mariangela Atteno, et al.
Expert Review of Clinical Immunology|March 10, 2020
Metabolic Syndrome and psoriatic arthritis: considerations for the clinicianFrancesco Caso, Maria Sole Chimenti, Luca Navarini, et al.
Pageof 22